Lilly To Deliver More Proof Points In Obesity, Keep Building Pipeline In 2024

Zepbound Readouts Expected In Co-Morbidities

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.

Lilly San Diego
Lilly will have readouts in obesity-related diseases for Zepbound in 2024 • Source: Shutterstock

Eli Lilly and Company’s obesity pipeline had a standout year in 2023 that will be hard to top in 2024, but the drug maker will continue delivering data to show the impact that significant weight loss with GLP-1/GIP agonist tirzepatide can have on related co-morbidities. And while the company awaits Phase III results from its next-generation obesity medicines retatrutide and orforglipron in 2025, it continues to scour the biopharmaceutical landscape for additional drug candidates.

Key Takeaways

  • Lilly will focus on its Zepbound launch and additional readouts for the obesity drug in 2024 while advancing its next-generation weight loss medicines.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.